The efficacy and safety of dupilumab in the treatment of dermatosis relating type 2 inflammatory response

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058210

Enrollment

Unknown

Registered

2022-04-01

Start date

2022-04-01

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bullous pemphigoid

Interventions

Experimental group:

Control group:

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The age is between 18 and 85 years, male or female; 2. Meet the diagnostic criteria of type 2 inflammatory related dermatoses; 3. Fully understand the research content, able to participate in the follow-up research behavior, willing to cooperate and participate in the whole process, and cooperate to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who may be allergic to the clinical trail drug or its components; 2. Those who suffer from other major systemic diseases or mental disorders that affect their follow-up cooperation; 3. Pregnancy and lactation patients; 4. Patients participating in other trials.

Design outcomes

Primary

Measure	Time frame
The time to disease control;	—

Secondary

Measure	Time frame
The control dose of methylprednisolone;The cumulative dosage of methylprednisolone;Percent change from baseline in disease-related scores;Remission rate;	—

Countries

China

Contacts

Public ContactXiaoqun Luo

Huashan Hospital Affiliated to Fudan University

luoxiaoqun913@126.com+86 13918825230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026